1
|
Bailey NA, Davis EP, Sandman CA, Glynn LM. DHEA: a neglected biological signal that may affect fetal and child development. J Child Psychol Psychiatry 2024; 65:1145-1155. [PMID: 38426566 DOI: 10.1111/jcpp.13952] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/05/2023] [Indexed: 03/02/2024]
Abstract
BACKGROUND The stress-sensitive maternal hypothalamic-pituitary-adrenal (HPA) axis through the end-product cortisol, represents a primary pathway through which maternal experience shapes fetal development with long-term consequences for child neurodevelopment. However, there is another HPA axis end-product that has been widely ignored in the study of human pregnancy. The synthesis and release of dehydroepiandosterone (DHEA) is similar to cortisol, so it is a plausible, but neglected, biological signal that may influence fetal neurodevelopment. DHEA also may interact with cortisol to determine developmental outcomes. Surprisingly, there is virtually nothing known about human fetal exposure to prenatal maternal DHEA and offspring neurodevelopment. The current study examined, for the first time, the joint impact of fetal exposure to prenatal maternal DHEA and cortisol on infant emotional reactivity. METHODS Participants were 124 mother-infant dyads. DHEA and cortisol were measured from maternal hair at 15 weeks (early gestation) and 35 weeks (late gestation). Observational assessments of positive and negative emotional reactivity were obtained in the laboratory when the infants were 6 months old. Pearson correlations were used to examine the associations between prenatal maternal cortisol, prenatal maternal DHEA, and infant positive and negative emotional reactivity. Moderation analyses were conducted to investigate whether DHEA might modify the association between cortisol and emotional reactivity. RESULTS Higher levels of both early and late gestation maternal DHEA were linked to greater infant positive emotional reactivity. Elevated late gestation maternal cortisol was associated with greater negative emotional reactivity. Finally, the association between fetal cortisol exposure and infant emotional reactivity was only observed when DHEA was low. CONCLUSIONS These new observations indicate that DHEA is a potential maternal biological signal involved in prenatal programming. It appears to act both independently and jointly with cortisol to determine a child's emotional reactivity. Its role as a primary end-product of the HPA axis, coupled with the newly documented associations with prenatal development shown here, strongly calls for the inclusion of DHEA in future investigations of fetal programming.
Collapse
Affiliation(s)
- Natasha A Bailey
- Department of Psychology, University of Virginia, Charlottesville, VA, USA
| | - Elysia Poggi Davis
- Department of Psychology, University of Denver, Denver, CO, USA
- Department of Pediatrics, University of California, Irvine, CA, USA
| | - Curt A Sandman
- Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA
| | - Laura M Glynn
- Department of Psychology, Chapman University, Orange, CA, USA
| |
Collapse
|
2
|
Armeni E, Lambrinoudaki I. Menopause, androgens, and cardiovascular ageing: a narrative review. Ther Adv Endocrinol Metab 2022; 13:20420188221129946. [PMID: 36325501 PMCID: PMC9619256 DOI: 10.1177/20420188221129946] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 09/09/2022] [Indexed: 11/07/2022] Open
Abstract
Cardiovascular disease is the leading cause of death worldwide; however, women tend to be less affected than men during their reproductive years. The female cardiovascular risk increases significantly around the time of the menopausal transition. The loss of the protective action of ovarian oestrogens and the circulating androgens has been implicated in possibly inducing subclinical and overt changes in the cardiovascular system after the menopausal transition. In vitro studies performed in human or animal cell lines demonstrate an adverse effect of testosterone on endothelial cell function and nitric oxide bioavailability. Cohort studies evaluating associations between testosterone and/or dehydroepiandrosterone and subclinical vascular disease and clinical cardiovascular events show an increased risk for women with more pronounced androgenicity. However, a mediating effect of insulin resistance is possible. Data on cardiovascular implications following low-dose testosterone treatment in middle-aged women or high-dose testosterone supplementation for gender affirmatory purposes remain primarily inconsistent. It is prudent to consider the possible adverse association between testosterone and endothelial function during the decision-making process of the most appropriate treatment for a postmenopausal woman.
Collapse
Affiliation(s)
| | - Irene Lambrinoudaki
- Second Department of Obstetrics and Gynecology, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece
| |
Collapse
|
3
|
Tang J, Chen LR, Chen KH. The Utilization of Dehydroepiandrosterone as a Sexual Hormone Precursor in Premenopausal and Postmenopausal Women: An Overview. Pharmaceuticals (Basel) 2021; 15:46. [PMID: 35056103 PMCID: PMC8781653 DOI: 10.3390/ph15010046] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2021] [Revised: 12/16/2021] [Accepted: 12/27/2021] [Indexed: 12/03/2022] Open
Abstract
Dehydroepiandrosterone (DHEA), and its metabolite, dehydroepiandrosterone sulfate ester (DHEAS), are the most abundant circulating steroid hormones, and are synthesized in the zona reticularis of the adrenal cortex, in the gonads, and in the brain. The precise physiological role of DHEA and DHEAS is not yet fully understood, but these steroid hormones can act as androgens, estrogens, and neurosteroids, and perform many roles in the human body. Since both levels decline with age, use of DHEA supplements have gained more attention due to being advertised as an antidote to aging in postmenopausal women, who may have concerns on age-related diseases and overall well-being. However, current research has not reached an overall consensus on the effects of DHEA on postmenopausal women. This overview is a summary of the current literature, addressing the metabolic pathway for DHEA synthesis and utilization, as well as the effects of DHEA on premenopausal and postmenopausal women with disease states and other factors. As for the therapeutic effects on menopausal syndrome and other age-related diseases, several studies have found that DHEA supplementations can alleviate vasomotor symptoms, preserve the integrity of the immune system, reduce bone loss, and increase muscle mass. Intravaginal DHEA has shown significant beneficial effects in menopausal women with severe vulvovaginal symptoms. On the other hand, DHEA supplements have not shown definitive effects in cardiovascular disease, adrenal insufficiency, insulin sensitivity, and cognition. Due to inadequate sample sizes and treatment durations of current studies, it is difficult to assess the safety and efficacy of DHEA and draw reliable conclusions for the physiological role, the optimal dosage, and the effects on premenopausal and postmenopausal women; therefore, the study of DHEA warrants future investigation. Further research into the roles of these steroid hormones may bring us closer to a therapeutic option in the future.
Collapse
Affiliation(s)
- Justine Tang
- School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan;
| | - Li-Ru Chen
- Department of Physical Medicine and Rehabilitation, Mackay Memorial Hospital, Taipei 104, Taiwan;
- Department of Mechanical Engineering, National Yang Ming Chiao Tung University, Hsinchu 300, Taiwan
| | - Kuo-Hu Chen
- Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 231, Taiwan
- School of Medicine, Tzu-Chi University, Hualien 970, Taiwan
| |
Collapse
|
4
|
Agrawal V, Lahm T, Hansmann G, Hemnes AR. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism. Cardiovasc Diagn Ther 2020; 10:1522-1540. [PMID: 33224772 PMCID: PMC7666935 DOI: 10.21037/cdt-20-404] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 06/04/2020] [Indexed: 12/17/2022]
Abstract
Pulmonary arterial hypertension (PAH) is a rare, life-threatening condition characterized by dysregulated metabolism, pulmonary vascular remodeling, and loss of pulmonary vascular cross-sectional area due to a variety of etiologies. Right ventricular (RV) dysfunction in PAH is a critical mediator of both long-term morbidity and mortality. While combinatory oral pharmacotherapy and/or intravenous prostacyclin aimed at decreasing pulmonary vascular resistance (PVR) have improved clinical outcomes, there are currently no treatments that directly address RV failure in PAH. This is, in part, due to the incomplete understanding of the pathogenesis of RV dysfunction in PAH. The purpose of this review is to discuss the current understanding of key molecular mechanisms that cause, contribute and/or sustain RV dysfunction, with a special focus on pathways that either have led to or have the potential to lead to clinical therapeutic intervention. Specifically, this review discusses the mechanisms by which vessel loss and dysfunctional angiogenesis, sex hormones, and metabolic derangements in PAH directly contribute to RV dysfunction. Finally, this review discusses limitations and future areas of investigation that may lead to novel understanding and therapeutic interventions for RV dysfunction in PAH.
Collapse
Affiliation(s)
- Vineet Agrawal
- Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Tim Lahm
- Department of Medicine, Indiana University, Indianapolis, IN, USA
| | - Georg Hansmann
- Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany
| | - Anna R. Hemnes
- Division of Allergy, Pulmonology and Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
5
|
Teixeira CJ, Veras K, de Oliveira Carvalho CR. Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period. J Mol Med (Berl) 2020; 98:39-57. [PMID: 31713639 DOI: 10.1007/s00109-019-01842-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2019] [Revised: 09/16/2019] [Accepted: 10/09/2019] [Indexed: 12/16/2022]
Abstract
Dehydroepiandrosterone (DHEA), mostly present as its sulfated ester (DHEA-S), is an anabolic hormone that naturally declines with age. Furthermore, it is the most abundant androgen and estrogen precursor in humans. Low plasma levels of DHEA have been strongly associated with obesity, insulin resistance, dyslipidemia, and high blood pressure, increasing the risk of cardiovascular disease. In this respect, DHEA could be regarded as a promising agent against metabolic syndrome (MetS) in postmenopausal women, since several age-related metabolic diseases are reported during aging. There are plenty of experimental evidences showing beneficial effects after DHEA therapy on carbohydrate and lipid metabolism, as well as cardiovascular health. However, its potential as a therapeutic agent appears to attract controversy, due to the lack of effects on some symptoms related to MetS. In this review, we examine the available literature regarding the impact of DHEA therapy on adiposity, glucose metabolism, and the cardiovascular system in the postmenopausal period. Both clinical studies and in vitro and in vivo experimental models were selected, and where possible, the main cellular mechanisms involved in DHEA therapy were discussed. Schematic representation showing some of the general effects observed after administration DHEA therapy on target tissues of energy metabolism and the cardiovascular system. ↑ represents an increase, ↓ represents a decrease, - represents a worsening and ↔ represents no change after DHEA therapy.
Collapse
Affiliation(s)
- Caio Jordão Teixeira
- Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, 105 Alexander Fleming St, Campinas, SP, 13083-881, Brazil
- Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, 1524 Prof. Lineu Prestes Ave., ICB 1, Sao Paulo, SP, 05508-900, Brazil
| | - Katherine Veras
- Department of Nutrition, University of Mogi das Cruzes, 200 Dr. Cândido X. A. Souza Ave., Sao Paulo, SP, 08780-911, Brazil
| | - Carla Roberta de Oliveira Carvalho
- Department of Physiology and Biophysics, Institute of Biomedical Science, University of Sao Paulo, 1524 Prof. Lineu Prestes Ave., ICB 1, Sao Paulo, SP, 05508-900, Brazil.
| |
Collapse
|
6
|
Hester J, Ventetuolo C, Lahm T. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure. Compr Physiol 2019; 10:125-170. [PMID: 31853950 DOI: 10.1002/cphy.c190011] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized by elevated pulmonary artery pressure and pulmonary vascular remodeling and that frequently lead to right ventricular (RV) failure and death. Several types of PH exhibit sexually dimorphic features in disease penetrance, presentation, and progression. Most sexually dimorphic features in PH have been described in pulmonary arterial hypertension (PAH), a devastating and progressive pulmonary vasculopathy with a 3-year survival rate <60%. While patient registries show that women are more susceptible to development of PAH, female PAH patients display better RV function and increased survival compared to their male counterparts, a phenomenon referred to as the "estrogen paradox" or "estrogen puzzle" of PAH. Recent advances in the field have demonstrated that multiple sex hormones, receptors, and metabolites play a role in the estrogen puzzle and that the effects of hormone signaling may be time and compartment specific. While the underlying physiological mechanisms are complex, unraveling the estrogen puzzle may reveal novel therapeutic strategies to treat and reverse the effects of PAH/PH. In this article, we (i) review PH classification and pathophysiology; (ii) discuss sex/gender differences observed in patients and animal models; (iii) review sex hormone synthesis and metabolism; (iv) review in detail the scientific literature of sex hormone signaling in PAH/PH, particularly estrogen-, testosterone-, progesterone-, and dehydroepiandrosterone (DHEA)-mediated effects in the pulmonary vasculature and RV; (v) discuss hormone-independent variables contributing to sexually dimorphic disease presentation; and (vi) identify knowledge gaps and pathways forward. © 2020 American Physiological Society. Compr Physiol 10:125-170, 2020.
Collapse
Affiliation(s)
- James Hester
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care, Occupational and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
| | - Corey Ventetuolo
- Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA.,Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA
| | - Tim Lahm
- Department of Medicine, Division of Pulmonary, Allergy, Critical Care, Occupational and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.,Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.,Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA
| |
Collapse
|
7
|
Falcón D, González-Montelongo R, Sánchez de Rojas-de Pedro E, Ordóñez A, Ureña J, Castellano A. Dexamethasone-induced upregulation of Ca V3.2 T-type Ca 2+ channels in rat cardiac myocytes. J Steroid Biochem Mol Biol 2018; 178:193-202. [PMID: 29262379 DOI: 10.1016/j.jsbmb.2017.12.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Revised: 11/21/2017] [Accepted: 12/14/2017] [Indexed: 12/27/2022]
Abstract
Glucocorticoids are widely used to treat acute and chronic diseases. Unfortunately, their therapeutic use is associated with severe side effects. Glucocorticoids are known to regulate several ion channels in cardiac myocytes, including voltage-dependent Ca2+ channels. Low-voltage-activated T-type Ca2+ channels are expressed in ventricular myocytes during the fetal and perinatal period, but are practically absent in the adult. However, these channels can be re-expressed in adult cardiomyocytes under some pathological conditions. We have investigated the glucocorticoid regulation of T-type Ca2+ channels in rat cardiomyocytes. Molecular studies revealed that dexamethasone induces the upregulation of CaV3.2 mRNA in neonatal rat ventricular myocytes, whereas CaV3.1 mRNA is only slightly affected. Patch-clamp recordings confirmed that T-type Ca2+ channel currents were upregulated in dexamethasone treated cardiomyocytes, and the addition of 50 μmol/L NiCl2 demonstrated that the CaV3.2 channel is responsible for this upregulation. The effect of dexamethasone on CaV3.2 is mediated by the activation and translocation to the cell nucleus of the glucocorticoid receptor (GR). We have isolated the upstream promoter of the Cacna1h gene and tested its activity in transfected ventricular myocytes. The initial in silico analysis of Cacna1h promoter revealed putative glucocorticoid response elements (GREs). Transcriptional activity assays combined with deletion analyses and chromatin immunoprecipitation assays demonstrated that GR binds to a region a GRE located in -1006/-985 bp of Cacna1h promoter. Importantly, upregulation of the CaV3.2 channel is also observed in vitro in adult rat ventricular myocytes, and in vivo in a rat model of excess of glucocorticoids.
Collapse
Affiliation(s)
- D Falcón
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain; Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain
| | - R González-Montelongo
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain; Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain
| | - E Sánchez de Rojas-de Pedro
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain
| | - A Ordóñez
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain; CIBERCV Instituto de Salud Carlos III, Madrid, Spain
| | - J Ureña
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain; Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain
| | - A Castellano
- Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/ Universidad de Sevilla, Sevilla, Spain; Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain.
| |
Collapse
|
8
|
Clark BJ, Prough RA, Klinge CM. Mechanisms of Action of Dehydroepiandrosterone. VITAMINS AND HORMONES 2018; 108:29-73. [PMID: 30029731 DOI: 10.1016/bs.vh.2018.02.003] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Dehydroepiandrosterone (3β-hydroxy-5-androsten-17-one, DHEA) and its sulfated metabolite DHEA-S are the most abundant steroids in circulation and decline with age. Rodent studies have shown that DHEA has a wide variety of effects on liver, kidney, adipose, reproductive tissues, and central nervous system/neuronal function. The mechanisms by which DHEA and DHEA-S impart their physiological effects may be direct actions on plasma membrane receptors, including a DHEA-specific, G-protein-coupled receptor in endothelial cells; various neuroreceptors, e.g., aminobutyric-acid-type A, N-methyl-d-aspartate (NMDA), and sigma-1 (S1R) receptors; by binding steroid receptors: androgen and estrogen receptors (ARs, ERα, or ERβ); or by their metabolism to more potent sex steroid hormones, e.g., testosterone, dihydrotestosterone, and estradiol, which bind with higher affinity to ARs and ERs. DHEA inhibits voltage-gated T-type calcium channels. DHEA activates peroxisome proliferator-activated receptor (PPARα) and CAR by a mechanism apparently involving PP2A, a protein phosphatase dephosphorylating PPARα and CAR to activate their transcriptional activity. We review our recent study showing DHEA activated GPER1 (G-protein-coupled estrogen receptor 1) in HepG2 cells to stimulate miR-21 transcription. This chapter reviews some of the physiological, biochemical, and molecular mechanisms of DHEA and DHEA-S activity.
Collapse
Affiliation(s)
- Barbara J Clark
- Department of Biochemistry and Molecular Genetics, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY, United States
| | - Russell A Prough
- Department of Biochemistry and Molecular Genetics, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY, United States
| | - Carolyn M Klinge
- Department of Biochemistry and Molecular Genetics, Center for Genetics and Molecular Medicine, University of Louisville School of Medicine, Louisville, KY, United States.
| |
Collapse
|
9
|
|
10
|
Kamin HS, Kertes DA. Cortisol and DHEA in development and psychopathology. Horm Behav 2017; 89:69-85. [PMID: 27979632 DOI: 10.1016/j.yhbeh.2016.11.018] [Citation(s) in RCA: 171] [Impact Index Per Article: 24.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Revised: 11/19/2016] [Accepted: 11/30/2016] [Indexed: 01/01/2023]
Abstract
Dehydroepiandrosterone (DHEA) and cortisol are the most abundant hormones of the human fetal and adult adrenals released as end products of a tightly coordinated endocrine response to stress. Together, they mediate short- and long-term stress responses and enable physiological and behavioral adjustments necessary for maintaining homeostasis. Detrimental effects of chronic or repeated elevations in cortisol on behavioral and emotional health are well documented. Evidence for actions of DHEA that offset or oppose those of cortisol has stimulated interest in examining their levels as a ratio, as an alternate index of adrenocortical activity and the net effects of cortisol. Such research necessitates a thorough understanding of the co-actions of these hormones on physiological functioning and in association with developmental outcomes. This review addresses the state of the science in understanding the role of DHEA, cortisol, and their ratio in typical development and developmental psychopathology. A rationale for studying DHEA and cortisol in concert is supported by physiological data on the coordinated synthesis and release of these hormones in the adrenal and by their opposing physiological actions. We then present evidence that researching cortisol and DHEA necessitates a developmental perspective. Age-related changes in DHEA and cortisol are described from the perinatal period through adolescence, along with observed associations of these hormones with developmental psychopathology. Along the way, we identify several major knowledge gaps in the role of DHEA in modulating cortisol in typical development and developmental psychopathology with implications for future research.
Collapse
Affiliation(s)
- Hayley S Kamin
- Department of Psychology, University of Florida, Gainesville, FL 32611, USA
| | - Darlene A Kertes
- Department of Psychology, University of Florida, Gainesville, FL 32611, USA; University of Florida Genetics Institute, University of Florida, Gainesville, FL 32611, USA.
| |
Collapse
|
11
|
DHEA-induced modulation of renal gluconeogenesis, insulin sensitivity and plasma lipid profile in the control- and dexamethasone-treated rabbits. Metabolic studies. Biochimie 2016; 121:87-101. [DOI: 10.1016/j.biochi.2015.11.019] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2015] [Accepted: 11/19/2015] [Indexed: 12/13/2022]
|
12
|
Mannic T, Satta N, Pagano S, Python M, Virzi J, Montecucco F, Frias MA, James RW, Maturana AD, Rossier MF, Vuilleumier N. CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes. Endocrinology 2015; 156:4707-19. [PMID: 26393305 DOI: 10.1210/en.2015-1605] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
In vitro and animal studies point to autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) as possible mediators of cardiovascular (CV) disease involving several mechanisms such as basal heart rate interference mediated by a mineralocorticoid receptor-dependent L-type calcium channel activation, and a direct pro-inflammatory effect through the engagement of the toll-like receptor (TLR) 2/CD14 complex. Nevertheless, the possible implication of these receptors in the pro-arrhythmogenic effect of anti-apoA-1 antibodies remains elusive. We aimed at determining whether CD14 and TLRs could mediate the anti-apoA-1 IgG chronotropic response in neonatal rat ventricular cardiomyocytes (NRVC). Blocking CD14 suppressed anti-apoA-1 IgG binding to NRVC and the related positive chronotropic response. Anti-apoA-1 IgG alone induced the formation of a TLR2/TLR4/CD14 complex, followed by the phosphorylation of Src, whereas aldosterone alone promoted the phosphorylation of Akt by phosphatidylinositol 3-kinase (PI3K), without affecting the chronotropic response. In the presence of both aldosterone and anti-apoA-1 IgG, the localization of TLR2/TLR4/CD14 was increased in membrane lipid rafts, followed by PI3K and Src activation, leading to an L-type calcium channel-dependent positive chronotropic response. Pharmacological inhibition of the Src pathway led to the decrease of L-type calcium channel activity and abrogated the NRVC chronotropic response. Activation of CD14 seems to be a key regulator of the mineralocorticoid receptor-dependent anti-apoA-1 IgG positive chronotropic effect on NRVCs, involving relocation of the CD14/TLR2/TLR4 complex into lipid rafts followed by PI3K and Src-dependent L-type calcium channel activation.
Collapse
Affiliation(s)
- Tiphaine Mannic
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nathalie Satta
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Sabrina Pagano
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Magaly Python
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Julien Virzi
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Fabrizio Montecucco
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Miguel A Frias
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Richard W James
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Andres D Maturana
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Michel F Rossier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| | - Nicolas Vuilleumier
- Human Protein Sciences Department, Chemistry and Proteomic Group, Auto-immunity and Atherogenesis group; and Division of Laboratory Medicine, Department of Genetics and Laboratory Medicine (T.M., N.S., J.V., F.M., N.V., M.F.R.), Geneva University Hospitals, 1201 Geneva, Switzerland; Department of Internal Medicine, Division of Endocrinology, Diabetology, Hypertension and Nutrition (M.P., M.A.F., R.W.J.), Geneva University Hospitals, Switzerland; Department of Bioengineering Sciences (A.D.M.), Graduate School of Bioagricultural Sciences, Furo-cho, Chikusa-ku, Nagoya 464-8601, Nagoya University, Japan; and Central Institute of the Hospital of Valais (M.F.R.), 1951 Sion, Switzerland
| |
Collapse
|
13
|
A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy. Int J Mol Sci 2015; 16:17456-68. [PMID: 26263970 PMCID: PMC4581202 DOI: 10.3390/ijms160817456] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 07/16/2015] [Accepted: 07/23/2015] [Indexed: 01/11/2023] Open
Abstract
Cytochrome P450 17A1 (CYP17A1) catalyses the formation and metabolism of steroid hormones. They are involved in blood pressure (BP) regulation and in the pathogenesis of left ventricular hypertrophy. Therefore, altered function of CYP17A1 due to genetic variants may influence BP and left ventricular mass. Notably, genome wide association studies supported the role of this enzyme in BP control. Against this background, we investigated associations between single nucleotide polymorphisms (SNPs) in or nearby the CYP17A1 gene with BP and left ventricular mass in patients with arterial hypertension and associated cardiovascular organ damage treated according to guidelines. Patients (n = 1007, mean age 58.0 ± 9.8 years, 83% men) with arterial hypertension and cardiac left ventricular ejection fraction (LVEF) ≥ 40% were enrolled in the study. Cardiac parameters of left ventricular mass, geometry and function were determined by echocardiography. The cohort comprised patients with coronary heart disease (n = 823; 81.7%) and myocardial infarction (n = 545; 54.1%) with a mean LVEF of 59.9% ± 9.3%. The mean left ventricular mass index (LVMI) was 52.1 ± 21.2 g/m2.7 and 485 (48.2%) patients had left ventricular hypertrophy. There was no significant association of any investigated SNP (rs619824, rs743572, rs1004467, rs11191548, rs17115100) with mean 24 h systolic or diastolic BP. However, carriers of the rs11191548 C allele demonstrated a 7% increase in LVMI (95% CI: 1%-12%, p = 0.017) compared to non-carriers. The CYP17A1 polymorphism rs11191548 demonstrated a significant association with LVMI in patients with arterial hypertension and preserved LVEF. Thus, CYP17A1 may contribute to cardiac hypertrophy in this clinical condition.
Collapse
|
14
|
Mannic T, Viguie J, Rossier MF. In vivo and in vitro evidences of dehydroepiandrosterone protective role on the cardiovascular system. Int J Endocrinol Metab 2015; 13:e24660. [PMID: 25926854 PMCID: PMC4389253 DOI: 10.5812/ijem.24660] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 12/05/2014] [Accepted: 02/14/2015] [Indexed: 02/06/2023] Open
Abstract
CONTEXT Dehydroepiandrosterone (DHEA) and its sulfate ester, Dehydroepiandrosterone Sulfate (DHEA-S) have been considered as putative anti-aging hormones for many years. Indeed, while DHEAS is the most abundant circulating hormone, its concentration is markedly decreased upon aging and early epidemiologic trials have revealed a strong inverse correlation between the hormone concentrations and the occurrence of several dysfunctions frequently encountered in the elderly. Naturally, hormonal supplementation has been rapidly suggested to prevent DHEA (S) deficiency and therefore, age-related development of these pathologies, using the same strategy as estrogen replacement therapy proposed in postmenopausal women. EVIDENCE ACQUISITION All references were searched using PubMed and the following strategy: our initial selection included all articles in English and we sorted them with the following keywords: "DHEA or DHEA-S" and "heart or vascular or endothelium or cardiovascular disease". The search was limited to neither the publication date nor specific journals. The final selection was made according to the relevance of the article content with the aims of the review. According to these criteria, fewer than 10% of the articles retrieved at the first step were discarded. RESULTS In this short review, we have focused on the cardiovascular action of DHEA. We started by analyzing evidences in favor of a strong inverse association between DHEA (S) levels and the cardiovascular risk as demonstrated in multiple observational epidemiologic studies for several decades. Then we discussed the different trials aimed at supplementing DHEA (S), both in animals and human, for preventing cardiovascular diseases and we analyzed the possible reasons for the discrepancy observed among the results of some studies. Finally, we presented putative molecular mechanisms of action for DHEA (S), demonstrated in vitro in different models of vascular and cardiac cells, highlighting the complexity of the involved signaling pathways. CONCLUSIONS The identification of the beneficial cardiovascular effects of DHEA (S) and a better understanding of the involved mechanisms should be helpful to develop new strategies or pharmacologic approaches for many lethal diseases in Western countries.
Collapse
Affiliation(s)
- Tiphaine Mannic
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Department of Genetics and laboratory Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland
- Corresponding author: Tiphaine Mannic, Department of Genetics and laboratory Medicine, University Hospitals of Geneva, University of Geneva, Geneva, Switzerland. Tel: +41-223795775, Fax: +41-223795502, E-mail:
| | - Joanna Viguie
- Department of Neurosciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Michel Florian Rossier
- Department of Human Protein Science, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- Service of Clinical Chemistry and Toxicology, Central Institute of the Hospital of Valais, Sion, Switzerland
| |
Collapse
|
15
|
Rawat DK, Alzoubi A, Gupte R, Chettimada S, Watanabe M, Kahn AG, Okada T, McMurtry IF, Gupte SA. Increased Reactive Oxygen Species, Metabolic Maladaptation, and Autophagy Contribute to Pulmonary Arterial Hypertension–Induced Ventricular Hypertrophy and Diastolic Heart Failure. Hypertension 2014; 64:1266-74. [DOI: 10.1161/hypertensionaha.114.03261] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Dhawjbahadur K. Rawat
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Abdallah Alzoubi
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Rakhee Gupte
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Sukrutha Chettimada
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Makino Watanabe
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Andrea G. Kahn
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Takao Okada
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Ivan F. McMurtry
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| | - Sachin A. Gupte
- From the Departments of Biochemistry and Molecular Biology (D.K.R., R.G., S.C., S.A.G.), Pharmacology (A.A., I.F.M.), Lung Biology (A.A., I.F.M., S.A.G.), Internal Medicine (I.F.M.), and Pathology (A.G.K.), University of South Alabama, College of Medicine, Mobile; and Department of Physiology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan (M.W., T.O.)
| |
Collapse
|
16
|
Ito J. [Steroid hormones' genomic and non-genomic actions on cardiac voltage-gated calcium channels]. Nihon Yakurigaku Zasshi 2014; 144:206-210. [PMID: 25381888 DOI: 10.1254/fpj.144.206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
|